98 related articles for article (PubMed ID: 22847294)
1. Overexpression of activated phospholipase Cγ1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy.
Lattanzio R; Marchisio M; La Sorda R; Tinari N; Falasca M; Alberti S; Miscia S; Ercolani C; Di Benedetto A; Perracchio L; Melucci E; Iacobelli S; Mottolese M; Natali PG; Piantelli M;
Int J Cancer; 2013 Mar; 132(5):1022-31. PubMed ID: 22847294
[TBL] [Abstract][Full Text] [Related]
2. PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes.
Lattanzio R; Iezzi M; Sala G; Tinari N; Falasca M; Alberti S; Buglioni S; Mottolese M; Perracchio L; Natali PG; Piantelli M
BMC Cancer; 2019 Jul; 19(1):747. PubMed ID: 31362705
[TBL] [Abstract][Full Text] [Related]
3. Phospholipase Cgamma1 is required for metastasis development and progression.
Sala G; Dituri F; Raimondi C; Previdi S; Maffucci T; Mazzoletti M; Rossi C; Iezzi M; Lattanzio R; Piantelli M; Iacobelli S; Broggini M; Falasca M
Cancer Res; 2008 Dec; 68(24):10187-96. PubMed ID: 19074886
[TBL] [Abstract][Full Text] [Related]
4. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
6. Phospholipase C-γ1 expression correlated with cancer progression of potentially malignant oral lesions.
Ma LW; Zhou ZT; He QB; Jiang WW
J Oral Pathol Med; 2013 Jan; 42(1):47-52. PubMed ID: 22671975
[TBL] [Abstract][Full Text] [Related]
7. BetaPix-a enhances the activity of phospholipase Cgamma1 by binding SH3 domain in breast cancer.
Bae JY; Ahn SJ; Lee JE; Kim JE; Han MR; Han W; Kim SW; Shin HJ; Lee SJ; Park D; Noh DY
J Cell Biochem; 2005 Apr; 94(5):1010-6. PubMed ID: 15597340
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
9. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.
Ladoire S; Arnould L; Mignot G; Coudert B; Rébé C; Chalmin F; Vincent J; Bruchard M; Chauffert B; Martin F; Fumoleau P; Ghiringhelli F
Breast Cancer Res Treat; 2011 Jan; 125(1):65-72. PubMed ID: 20229175
[TBL] [Abstract][Full Text] [Related]
10. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
[TBL] [Abstract][Full Text] [Related]
11. Concurrent chemotherapy and radiation for breast conservation treatment of early-stage breast cancer.
Markiewicz DA; Fox KR; Schultz DJ; Harris EE; Haas JA; Glick JH; Solin LJ
Cancer J Sci Am; 1998; 4(3):185-93. PubMed ID: 9612601
[TBL] [Abstract][Full Text] [Related]
12. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
13. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
[TBL] [Abstract][Full Text] [Related]
14. CXCR4 expression in early breast cancer and risk of distant recurrence.
Andre F; Xia W; Conforti R; Wei Y; Boulet T; Tomasic G; Spielmann M; Zoubir M; Berrada N; Arriagada R; Hortobagyi GN; Hung MC; Pusztai L; Delaloge S; Michiels S; Cristofanilli M
Oncologist; 2009 Dec; 14(12):1182-8. PubMed ID: 19939894
[TBL] [Abstract][Full Text] [Related]
15. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
16. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.
Mook S; Schmidt MK; Rutgers EJ; van de Velde AO; Visser O; Rutgers SM; Armstrong N; van't Veer LJ; Ravdin PM
Lancet Oncol; 2009 Nov; 10(11):1070-6. PubMed ID: 19801202
[TBL] [Abstract][Full Text] [Related]
17. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
[TBL] [Abstract][Full Text] [Related]
18. DNA flow cytometry but not telomerase activity as predictor of disease-free survival in pT1-2/N0/G2 breast cancer.
Pinto AE; André S; Pereira T; Silva G; Soares J
Pathobiology; 2006; 73(2):63-70. PubMed ID: 16943686
[TBL] [Abstract][Full Text] [Related]
19. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
[TBL] [Abstract][Full Text] [Related]
20. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
Bertucci F; Finetti P; Viens P; Birnbaum D
Cancer Lett; 2014 Dec; 355(1):70-5. PubMed ID: 25218596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
